Isla, D.; Sánchez, A.; Casal, J.; Cobo, M.; Majem, M.; Reguart, N.; Zugazagoitia, J.; Bernabé, R.
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. J. Clin. Med. 2023, 12, 5063.
https://doi.org/10.3390/jcm12155063
AMA Style
Isla D, Sánchez A, Casal J, Cobo M, Majem M, Reguart N, Zugazagoitia J, Bernabé R.
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15):5063.
https://doi.org/10.3390/jcm12155063
Chicago/Turabian Style
Isla, Dolores, Alfredo Sánchez, JoaquÃn Casal, Manuel Cobo, Margarita Majem, Noemi Reguart, Jon Zugazagoitia, and Reyes Bernabé.
2023. "PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement" Journal of Clinical Medicine 12, no. 15: 5063.
https://doi.org/10.3390/jcm12155063
APA Style
Isla, D., Sánchez, A., Casal, J., Cobo, M., Majem, M., Reguart, N., Zugazagoitia, J., & Bernabé, R.
(2023). PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine, 12(15), 5063.
https://doi.org/10.3390/jcm12155063
